Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
Speciation of arsenic trioxide metabolites in peripheral blood and bone marrow from an acute promyelocytic leukemia patient.
Iriyama N, Yoshino Y, Yuan B, Horikoshi A, Hirabayashi Y, Hatta Y, Toyoda H, Takeuchi J.
J Hematol Oncol. 2012 Jan 24;5:1.
Related citations
Speciation of arsenic trioxide metabolites in blood cells and plasma of a patient with acute promyelocytic leukemia.
Yoshino Y, Yuan B, Miyashita SI, Iriyama N, Horikoshi A, Shikino O, Toyoda H, Kaise T.
Anal Bioanal Chem. 2009 Jan;393(2):689-97. Epub 2008 Nov 14.
Clinical pharmacokinetic study of arsenic trioxide in an acute promyelocytic leukemia (APL) patient: speciation of arsenic metabolites in serum and urine.
Fukai Y, Hirata M, Ueno M, Ichikawa N, Kobayashi H, Saitoh H, Sakurai T, Kinoshita K, Kaise T, Ohta S.
Biol Pharm Bull. 2006 May;29(5):1022-7.
Pharmacokinetics of arsenic species in Japanese patients with relapsed or refractory acute promyelocytic leukemia treated with arsenic trioxide.
Fujisawa S, Ohno R, Shigeno K, Sahara N, Nakamura S, Naito K, Kobayashi M, Shinjo K, Takeshita A, Suzuki Y, Hashimoto H, Kinoshita K, Shimoya M, Kaise T, Ohnishi K.
Cancer Chemother Pharmacol. 2007 Mar;59(4):485-93. Epub 2006 Aug 26.
Arsenic speciation in urine from acute promyelocytic leukemia patients undergoing arsenic trioxide treatment.
Wang Z, Zhou J, Lu X, Gong Z, Le XC.
Chem Res Toxicol. 2004 Jan;17(1):95-103.
Speciation of arsenic trioxide penetrates into cerebrospinal fluid in patients with acute promyelocytic leukemia.
Kiguchi T, Yoshino Y, Yuan B, Yoshizawa S, Kitahara T, Akahane D, Gotoh M, Kaise T, Toyoda H, Ohyashiki K.
Leuk Res. 2010 Mar;34(3):403-5. Epub 2009 Sep 4.
Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide.
Soignet SL, Maslak P, Wang ZG, Jhanwar S, Calleja E, Dardashti LJ, Corso D, DeBlasio A, Gabrilove J, Scheinberg DA, Pandolfi PP, Warrell RP Jr.
N Engl J Med. 1998 Nov 5;339(19):1341-8.
Final Report on Carcinogens Background Document for Formaldehyde.
National Toxicology Program.
Rep Carcinog Backgr Doc. 2010 Jan;(10-5981):i-512.
Final Report on Carcinogens Background Document for Styrene.
Rep Carcinog Backgr Doc. 2008 Sep;(8-5978):i-398.
Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients.
Shen ZX, Chen GQ, Ni JH, Li XS, Xiong SM, Qiu QY, Zhu J, Tang W, Sun GL, Yang KQ, Chen Y, Zhou L, Fang ZW, Wang YT, Ma J, Zhang P, Zhang TD, Chen SJ, Chen Z, Wang ZY.
Blood. 1997 May 1;89(9):3354-60.
Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy.
Ghavamzadeh A, Alimoghaddam K, Ghaffari SH, Rostami S, Jahani M, Hosseini R, Mossavi A, Baybordi E, Khodabadeh A, Iravani M, Bahar B, Mortazavi Y, Totonchi M, Aghdami N.
Ann Oncol. 2006 Jan;17(1):131-4. Epub 2005 Oct 14.
Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy.
Zhou GB, Zhang J, Wang ZY, Chen SJ, Chen Z.
Philos Trans R Soc Lond B Biol Sci. 2007 Jun 29;362(1482):959-71. Review.
Long-term remission after first-line single-agent treatment with arsenic trioxide of relapsed acute promyelocytic leukemia in an 8-year-old boy.
Ebinger M, Schwarze CP, Feuchtinger T, Scheel-Walter HG, Lang P, Hildenbrand S, Gessler P, Handgretinger R.
Pediatr Hematol Oncol. 2011 May;28(4):334-7. Epub 2011 Feb 23.
Determination of arsenic species in fish, crustacean and sediment samples from Thailand using high performance liquid chromatography (HPLC) coupled with inductively coupled plasma mass spectrometry (ICP-MS).
Rattanachongkiat S, Millward GE, Foulkes ME.
J Environ Monit. 2004 Apr;6(4):254-61. Epub 2004 Mar 19.
Application of fast ultrasound water-bath assisted enzymatic hydrolysis--high performance liquid chromatography-inductively coupled plasma-mass spectrometry procedures for arsenic speciation in seafood materials.
Moreda-Piñeiro A, Moreda-Piñeiro J, Herbello-Hermelo P, Bermejo-Barrera P, Muniategui-Lorenzo S, López-Mahía P, Prada-Rodríguez D.
J Chromatogr A. 2011 Sep 28;1218(39):6970-80. Epub 2011 Aug 6.
Arsenic trioxide therapy in relapsed or refractory Japanese patients with acute promyelocytic leukemia: updated outcomes of the phase II study and postremission therapies.
Shigeno K, Naito K, Sahara N, Kobayashi M, Nakamura S, Fujisawa S, Shinjo K, Takeshita A, Ohno R, Ohnishi K.
Int J Hematol. 2005 Oct;82(3):224-9.
Increased cellular glutathione and protection by bone marrow stromal cells account for the resistance of non-acute promylocytic leukemia acute myeloid leukemia cells to arsenic trioxide in vivo.
Lee C, Lin Y, Huang M, Lin C, Liu C, Chow J, Liu HE.
Leuk Lymphoma. 2006 Mar;47(3):521-9.
Comparison of clinical outcomes of patients with relapsed acute promyelocytic leukemia induced with arsenic trioxide and consolidated with either an autologous stem cell transplant or an arsenic trioxide-based regimen.
Thirugnanam R, George B, Chendamarai E, Lakshmi KM, Balasubramanian P, Viswabandya A, Srivastava A, Chandy M, Mathews V.
Biol Blood Marrow Transplant. 2009 Nov;15(11):1479-84. Epub 2009 Sep 1.
Arsenic metabolism in multiple myeloma and astrocytoma cells.
Falnoga I, Slejkovec Z, Pucer A, Podgornik H, Tusek-Znidaric M.
Biol Trace Elem Res. 2007 Apr;116(1):5-28.
Arsenic trioxide as first-line treatment for acute promyelocytic leukemia.
Leu L, Mohassel L.
Am J Health Syst Pharm. 2009 Nov 1;66(21):1913-8.
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on